Multicenter, retrospective, and observational study of afatinib treatment in patients with non-small cell lung cancer harboring EGFR mutation who previously treated with EGFR-TKI.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2015
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 28 Sep 2015 Status changed from not yet recruiting to discontinued,as reported by University Hospital Medical Information Network - Japan record.
- 31 Mar 2015 New trial record